Evidence map›Paper›PMID 37415045›Full record

ArticleInflammation2023

Coordinated Priming of NKG2D Pathway by IL-15 Enhanced Functional Properties of Cytotoxic CD4

Tingting Wang, Laiyou Wei, Shuhui Meng, Wencong Song, Yulan Chen, Heng Li, Qianqian Zhao, Zhenyou Jiang, Dongzhou Liu, Huan Ren and 1 more

Open access · hybridAbstract readLetter
In one paragraph

Article in Inflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Cytotoxic CD4Signal transduction and targeted therapy · 2026
    Review
  3. Article
  4. Article
  5. Interleukin 15 and autoimmune disorders: pathophysiology, therapeutic potential, and clinical implications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  6. Targeting PD-1 and CD85j can restore intratumoral CD4Journal for immunotherapy of cancer · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Tingting Wang *Department of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.
Laiyou Wei *School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
Shuhui MengDepartment of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.
Wencong SongDepartment of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.
Yulan ChenDepartment of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.
Heng LiDepartment of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.
Qianqian ZhaoDepartment of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.
Zhenyou JiangDepartment of Microbiology and Immunology, College of Basic Medicine and Public Hygiene, Jinan University, Guangzhou, 510632, China.
Dongzhou LiuDepartment of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.
Huan RenSchool of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China. hong_xiaoping@hotmail.com.
Xiaoping HongDepartment of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China. renh@sustech.edu.cn.
Jinan University · CNSouthern University of Science and Technology · CNShenzhen Second People's Hospital · CN

Funding

Guangdong Basic and Applied Basic Research Fund 2021A1515111072National Natural Science Foundation of China 81971464National Natural Science Foundation of China 82201996Science and innovation commission of shenzhen municipality JCYJ20220530151811025
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder, and numerous aberrations of T cell responses have been reported and were implicated in its pathophysiology. Recently, CD4-positive T cells with cytotoxic potential were shown to be involved in autoimmune disease progression and tissue damage. However, the effector functions of this cell type and their potential molecular mechanisms in SLE patients remain to be elucidated. In this study, we find that cytotoxic CD4

Indexed as

Antineoplastic AgentsLupus Erythematosus, SystemicCD28 AntigensCD4-Positive T-LymphocytesHumansInterleukin-15NK Cell Lectin-Like Receptor Subfamily KPhosphatidylinositol 3-KinasesAntineoplastic AgentsCD28 AntigensInterleukin-15NK Cell Lectin-Like Receptor Subfamily KPhosphatidylinositol 3-Kinasescytolytic functioncytotoxic CD4+CD28− T cellsinflammationinterleukin-15-NKG2Dtissue damage

Identifiers

PMID37415045
PMCPMC10567942
OpenAlexW4383314386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.